Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients

Next Previous
Trial Profile

An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 101 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Immodulon Therapeutics

Most Recent Events

  • 21 Nov 2019 According to an Immodulon Therapeutics media release, positive results from this phase 1 follow up study supports current phase 2 clinical trial(NCT03711188) of IMM-101 in combination with checkpoint inhibitor therapy.
  • 21 Nov 2019 According to an Immodulon Therapeutics media release, Dr Alberto Fusi is the principle investigator of the study.
  • 21 Nov 2019 Results published in the Immodulon Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top